Primary care respiratory journal : journal of the General Practice Airways Group · 2013
Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Price David, Lee Amanda J, Sims Erika J, Kemp Linda, Hillyer Elizabeth V, Chisholm Alison, von Ziegenweidt Julie, Williams Angela
Аннотация
BACKGROUND: Patient preference is an important factor when choosing an inhaler device for asthma or chronic obstructive pulmonary disease (COPD).
AIMS: To identify characteristics of patients with asthma or COPD who prefer a once-daily controller medication regimen.
METHODS: This retrospective observational study used electronic patient records and linked outcomes from patient-completed questionnaires in a primary care database. We compared the characteristics of patients indicating a preference for once-daily therapy with those who were unsure or indicating no preference.
RESULTS: Of 3,731 patients with asthma, 2,174 (58%) were women; the mean age was 46 years (range 2-94). Of 2,138 patients with COPD, 980 (46%) were women; the mean age was 70 years (range 35-98). Approximately half of the patients in each cohort indicated once-daily preference, one-quarter were unsure, and one-quarter did not prefer once-daily therapy. In patients with asthma or COPD, the preference for once-daily controller medication was significantly associated with poor adherence and higher concerns about medication. In asthma, good control and low self-perceived controller medication need were associated with once-daily preference. By contrast, in COPD, a high self-perceived need for controller medication was associated with once-daily preference. There was no significant relationship between once-daily preference and age, sex, disease severity, or exacerbation history.
CONCLUSIONS: Understanding patient preferences may help prescribers to individualise therapy better for asthma and COPD.
AIMS: To identify characteristics of patients with asthma or COPD who prefer a once-daily controller medication regimen.
METHODS: This retrospective observational study used electronic patient records and linked outcomes from patient-completed questionnaires in a primary care database. We compared the characteristics of patients indicating a preference for once-daily therapy with those who were unsure or indicating no preference.
RESULTS: Of 3,731 patients with asthma, 2,174 (58%) were women; the mean age was 46 years (range 2-94). Of 2,138 patients with COPD, 980 (46%) were women; the mean age was 70 years (range 35-98). Approximately half of the patients in each cohort indicated once-daily preference, one-quarter were unsure, and one-quarter did not prefer once-daily therapy. In patients with asthma or COPD, the preference for once-daily controller medication was significantly associated with poor adherence and higher concerns about medication. In asthma, good control and low self-perceived controller medication need were associated with once-daily preference. By contrast, in COPD, a high self-perceived need for controller medication was associated with once-daily preference. There was no significant relationship between once-daily preference and age, sex, disease severity, or exacerbation history.
CONCLUSIONS: Understanding patient preferences may help prescribers to individualise therapy better for asthma and COPD.
Предметные рубрики MeSH
Administration, InhalationAdolescentAdultAgedAged, 80 and overAnti-Asthmatic AgentsAsthmaBronchodilator AgentsChildChild, PreschoolFemaleHumansMaleMedication AdherenceMiddle AgedPatient PreferencePulmonary Disease, Chronic ObstructiveRetrospective StudiesSurveys and QuestionnairesYoung AdultDrug Monitoring